These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 21793175)

  • 1. Treatment of children with poor risk solid tumors by further escalation of the VETOPEC regimen including very high-dose cyclophosphamide and peripheral stem cell support: an Australian and New Zealand Children's Hematology and Oncology Group study.
    McCowage GB; Mrongovius R; Alvaro F; Cohn RJ; Ziegler DS; Oswald C; White L;
    Pediatr Blood Cancer; 2011 Dec; 57(6):958-64. PubMed ID: 21793175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of vincristine and etoposide with escalating cyclophosphamide in poor-prognosis pediatric brain tumors.
    Ziegler DS; Cohn RJ; McCowage G; Alvaro F; Oswald C; Mrongovius R; White L;
    Neuro Oncol; 2006 Jan; 8(1):53-9. PubMed ID: 16443948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
    Schenkein DP; Roitman D; Miller KB; Morelli J; Stadtmauer E; Pecora AL; Cassileth P; Fernandez H; Cooper BW; Kutteh L; Lazarus HM
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):210-6. PubMed ID: 9360783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
    Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW
    Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-intensive, cyclophosphamide-based regimen for the treatment of recurrent/progressive or advanced solid tumors of childhood: a report from the Australia and New Zealand Children's Cancer Study Group.
    Carpenter PA; White L; McCowage GB; Nayanar V; Toogood I; Shaw PJ; Lockwood L; Tiedemann K
    Cancer; 1997 Aug; 80(3):489-96. PubMed ID: 9241083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-intensive cyclophosphamide with etoposide and vincristine for pediatric solid tumors: a phase I/II pilot study by the Australia and New Zealand Childhood Cancer Study Group.
    White L; McCowage G; Kannourakis G; Nayanar V; Colnan L; Kellie S; Shaw P; Seshadri R; Lockwood L; Tiedemann K
    J Clin Oncol; 1994 Mar; 12(3):522-31. PubMed ID: 8120550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of tandem high-dose chemotherapy with autologous peripheral blood stem cell rescue for children with recurrent brain tumors: a Pediatric Blood and MarrowTransplant Consortium study.
    Gilman AL; Jacobsen C; Bunin N; Levine J; Goldman F; Bendel A; Joyce M; Anderson P; Rozans M; Wall DA; Macdonald TJ; Simon S; Kadota RP
    Pediatr Blood Cancer; 2011 Sep; 57(3):506-13. PubMed ID: 21744474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term survival following a phase I/II trial with VETOPEC for solid tumors in childhood.
    Ziegler DS; McCowage G; Cohn RJ; White L
    J Pediatr Hematol Oncol; 2006 Jan; 28(1):40-2. PubMed ID: 16394892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study.
    Rheingold SR; Hogarty MD; Blaney SM; Zwiebel JA; Sauk-Schubert C; Chandula R; Krailo MD; Adamson PC;
    J Clin Oncol; 2007 Apr; 25(12):1512-8. PubMed ID: 17442993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N; Kloess M; Reiser M; Berdel WE; Metzner B; Dorken B; Kneba M; Trumper L; Loeffler M; Pfreundschuh M; Glass B;
    Cancer; 2006 Jan; 106(1):136-45. PubMed ID: 16331635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiagent chemotherapy studied in a xenograft model of medulloblastoma/primitive neuroectodermal tumour: analysis of the VETOPEC regimen.
    White L; Sterling-Levis K
    J Clin Neurosci; 2008 Jan; 15(1):49-54. PubMed ID: 18036819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue.
    Zacharoulis S; Levy A; Chi SN; Gardner S; Rosenblum M; Miller DC; Dunkel I; Diez B; Sposto R; Ji L; Asgharzadeh S; Hukin J; Belasco J; Dubowy R; Kellie S; Termuhlen A; Finlay J
    Pediatr Blood Cancer; 2007 Jul; 49(1):34-40. PubMed ID: 16874765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
    Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
    Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose thiotepa and etoposide in children with poor-prognosis brain tumors.
    Fagioli F; Biasin E; Mastrodicasa L; Sandri A; Ferrero I; Berger M; Vassallo E; Madon E
    Cancer; 2004 May; 100(10):2215-21. PubMed ID: 15139067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
    Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
    J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.